Every material Form 8-K Research Alliance Corp III has filed with the SEC since May 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
SPAC Research Alliance Corporation III (RACC) signed a business combination agreement on July 26, 2026 to acquire 100% of OHB Pediatrics Ltd., doing business as Oak Hill Bio, in exchange for newly issued RACC common stock. The combined company would be renamed Oak Hill Bio, Inc. and trade on Nasdaq as OAKH, with closing expected by year-end 2026 subject to shareholder approval and other conditions.
Base equity value of $160 million, plus a SAFE amount, divided by $10.00 per share sets the share count issued to Oak Hill Bio shareholders
Expected gross proceeds of about $175 million, including $75 million from RACC's trust account backstopped by RA Capital and a $100 million private financing
RACC shareholders may redeem Class A shares for cash from the trust account in connection with the transaction
Either party may terminate if the deal is not closed within six months of the agreement date, subject to extension provisions
Research Alliance Corporation III, a blank check company, closed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share on May 21, 2026, generating gross proceeds of $75 million before underwriting discounts and offering expenses. The full $75 million was deposited in a trust account for public shareholders, and the company has not yet selected a business combination target.
IPO of 7,500,000 Class A ordinary shares at $10.00 per share, closed May 21, 2026
Private placement of 275,000 Class A shares to sponsor Research Alliance Holdings III LLC for $2.75 million
$75 million placed in trust account with Continental Stock Transfer & Trust Company as trustee
Company has 24 months from IPO closing to complete a business combination, per the filing's Note 1
Research Alliance Corporation III, a blank check company, completed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share on May 21, 2026, for gross proceeds of $75,000,000 before underwriting discounts and offering expenses. The full $75,000,000 of net proceeds from the IPO and private placement, including a $2,250,000 deferred underwriter commission, was deposited in a trust account for public shareholders, and the company's letter agreements contemplate liquidation if a business combination is not completed within 24 months of the IPO closing.
IPO of 7,500,000 Class A ordinary shares at $10.00 per share, with gross proceeds of $75,000,000, consummated May 21, 2026
$75,000,000 deposited in trust account with Continental Stock Transfer & Trust Company as trustee, including a $2,250,000 deferred underwriter commission
Sponsor bought 275,000 private placement shares at $10.00 per share for $2,750,000, with transfer restrictions until 30 days after an initial business combination
Michael F. MacLean and Timothy J. Miller joined the board on May 19, 2026; MacLean chairs the Audit Committee and Miller chairs the Nominating and Compensation committees
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Research Alliance Corp III filing is on SEC EDGAR ↗. 8-K briefs of other companies →